skip to Main Content

Bloating Survey: Coordinated Study With Rome Foundation Research Institute and Danone Nutricia Research

Danone Nutricia Research and the Rome Foundation Research Institute (RFRI) have joined forces to launch an unprecedented survey aiming to uncover the frequency and severity of gastrointestinal symptoms (ex: bloating) their potential determinants and their impact on quality of life in the general adult population of three countries: The United States, Mexico and United Kingdom. The study will combine in the same large-scale assessment of a multi-national population sample the use of the newly validated Intestinal Gas Questionnaire (IGQ), diagnostic evaluation of functional bloating/distention with the Rome IV diagnostic criteria and lifestyle parameters. A sub-study will be carried out in each country for comprehensive assessment of dietary patterns and nutritional intake. The Researcher hope to unlock the link between diet, lifestyle and gut discomfort, paving the way forward in personal nutrition.

 

ROBOT- Rome Foundation BioMarker & Phenotyping Project

The aim of this ROme foundation BiOmarker and phenotyping projecT (ROBOT) is to develop a state-of-the-art biobank and database of patients with DGBI supported by an international network of top international researcher sites. Patients in the database will be thoroughly characterized with regard to their clinical phenotype and associated demographic, medical history, psychosocial and lifestyle factors, their fecal, blood and urine samples will be collected and stored in a standardized fashion, and in select sites also biopsies from the upper and/or lower GI tract depending on the predominant symptomatology. This biosample and data collection will be uniform across all sites and will enable evaluation of different biomarkers in large groups of very well-characterized individuals in different parts of the world and to assess their ability to be used as diagnostic and /or predictive tools. A centralized electronic database will enable development of profiles of available clinical phenotypes and biosamples at any time to assess the feasibility of new studies.

Back To Top